|
|
Vaccine Detail
|
CAR G36-PDL1 |
| Vaccine Information |
- Vaccine Name: CAR G36-PDL1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Other
- Status: Research
- Host Species for Licensed Use: None
- Antigen: human leukocyte antigen (HLA) (Wang et al., 2024)
- Immunization Route: Other
- Description: Chimeric antigen receptor (CAR) T cells can be used to treat solid tumors. These CAR-T cells are engineered to target carbonic anhydrase IX (CAIX) to secrete anti-PD-L1 monoclonal antibody (mAb), termed immune-restoring (IR) CAR G36-PDL1. The T cells can be used to treat clear cell renal cell carcinoma (ccRCC) with reconstituted human leukocyte antigen (HLA) partially matched human leukocytes derived from fetal CD34+ hematopoietic stem cells (HSCs) and bearing human ccRCC skrc-59 cells under the kidney capsule. The cells can restore active antitumor immunity by promoting tumor-killing cytotoxicity, reducing immunosuppressive cell components such as M2 macrophages and exhausted CD8+ T cells, and enhancing T follicular helper (Tfh)-B cell crosstalk. (Wang et al., 2024)
|
| Host Response |
|
|
| References |
Wang et al., 2024: Wang Y, Cho JW, Kastrunes G, Buck A, Razimbaud C, Culhane AC, Sun J, Braun DA, Choueiri TK, Wu CJ, Jones K, Nguyen QD, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman GJ, Hemberg M, Marasco WA. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. iScience. 2024; 27(2); 108879. [PubMed: 38327771].
|
|
